The art of producing recombinant proteins with complex post-translational modifications represents a major challenge for studies of structure and function. The rapid establishment and high recovery from transientlytransfected mammalian cell lines addresses this barrier and is an effective means of expressing proteins that are naturally channeled through the ER and Golgi-mediated secretory pathway. Here is one protocol for protein expression using the human HEK293F and HEK293S cell lines transfected with a mammalian expression vector designed for high protein yields. The applicability of this system is demonstrated using three representative glycoproteins that expressed with yields between 95-120 mg of purified protein recovered per liter of culture. These proteins are the human FcγRIIIa and the rat α2-6 sialyltransferase, ST6GalI, both expressed with an N-terminal GFP fusion, as well as the unmodified human immunoglobulin G1 Fc. This robust system utilizes a serum-free medium that is adaptable for expression of isotopically enriched proteins and carbohydrates for structural studies using mass spectrometry and nuclear magnetic resonance spectroscopy. Furthermore, the composition of the N-glycan can be tuned by adding a small molecule to prevent certain glycan modifications in a manner that does not reduce yield. 
Introduction
Producing high yields of appropriately folded and post-translationally modified human proteins for detailed analysis of structure and function remains a significant challenge. A large number of expression systems are available that produce recombinant proteins with native-like function and behavior. Bacterial expression systems, predominantly Escherichia coli strains, represent the most accessible and commonly used tools in the research arena, due to the simplicity of these expression systems, though yeast, plant, insect and mammalian systems are also described [1] [2] [3] [4] . However, the majority of these systems are incapable of appropriate post-translational modification of the target proteins. A fundamental interest of the Barb and Moremen laboratories is producing eukaryotic proteins with appropriate glycosylation. Many human proteins require appropriate glycosylation for proper function (see 5 ).
The eukaryotic glycosylation machinery is extensive and capable of making a diverse range of modifications, including both asparagine(N)-and serine/threonine(O)-linked complex glycans 6 . It is estimated that >50% of human proteins are N-glycosylated 7 . Glycans are essential components of many proteins including therapeutic monoclonal antibodies, erythropoietin, and blood clotting factors like factor IX, to name a few. Though multiple methods exist to prepare appropriately N-glycosylated proteins and range from purely synthetic [8] [9] [10] , to chemoenzymatic [11] [12] [13] [14] or recovery from engineered recombinant systems [15] [16] [17] [18] [19] [20] , not surprisingly, human expression systems have thus far proven to be the most robust methods for generating human proteins.
Many therapeutic human glycoproteins are produced in recombinant systems using mammalian cells. Systems of note are the Chinese Hamster Ovary (CHO), mouse myeloma (NS0), Baby Hamster Kidney (BHK), Human Embryonic Kidney (HEK-293) and human retinal cell lines that are employed in adhesion or suspension culture for protein production 4, 21, 22 . However, mammalian protein expression systems have required the generation of stable cell lines, expensive growth media and substrate assisted transfection procedures 23 .
Mammalian cell transfection is achieved with the aid of numerous agents including calcium phosphates 24, 25 , cationic polymers (DEAE-dextran, polybrene, polylysine, polyethylimine (PEI)) or positively charged cationic liposomes [26] [27] [28] [29] . PEI is a polycationic, charged, linear or branched polymer (25 kDa) 26 that forms a stable complex with DNA and is endocytosed. Upon acidification of the endosome, PEI is thought to swell, leading to the rupture of endosomes and release of the DNA into the cytoplasm 26, 30 .
Until recently, transient transfection in suspension culture was carried by prior DNA/PEI complex formation followed by addition to the cell culture 29 . However, Würm and coworkers reported a highly efficient protocol optimized for recombinant protein production in HEK293 cells that formed a DNA/PEI complex in situ . Herein is a method that builds upon these advances and is broadly applicable. Expression conditions may also be altered to impact the N-glycan composition.
The HEK293S cell line, with a gene deletion that halts N-glycan processing at an intermediate stage, leads to the expression of proteins with uniform N-glycans consisting of 2 N-acetylglucosamine residues plus five mannose residues (Man 5 GlcNAc 2 ) 34, 35 . These cells lack the N-acetylglucosaminyl transferase I (GntI) gene which is required for downstream N-glycan processing 36, 37 . The use of glycosyltransferase inhibitors including kifunensine, sialic acid analogs and the fucose analog and 2-deoxy-2-fluoro-fucose has similar effects and limits N-glycan processing [38] [39] [40] [41] .
The protocol reported here uses the pGEn2 vector as shown in Figure 1 42, 43 , PEI assisted transient transfection into mammalian cells lines (HEK293F or HEK293S cells), and the recovery of high yields of appropriately glycosylated protein. This system is robust and can accommodate various factors including isotope labeling and glycan engineering for the production of large titers of recombinant proteins.
Protocol
This protocol is sufficient for expression using either HEK293F or HEK293S cells.
Cell Establishment

Culture Inoculation
Note: All culture manipulation procedures must be carried in a BSL-2 facility and each item brought into the biosafety cabinet must be sterilized by spraying with a 70% ethanol in water solution.
1. Operate the incubator shaker at 135 rpm, 80% humidity and at 8.0% CO 2 and 37 °C. Turn "on" the UV lamp of the biosafety cabinet at least 1 h prior to working. Prewarm the sealed Medium A and Medium B bottles in the water-bath at 37 °C for 1 hr. 2. Sterilize 125 ml Erlenmeyer growth flasks with a vented cap, pipettes, pipettors, and prewarmed Media bottles by spraying with the 70% ethanol in water solution. Place these items in the biosafety cabinet. Note: Sterilize only the outer plastic covering the 125 ml Erlenmeyer culture flask, and then remove only when it is inside the biosafety cabinet. 3. For a 30 ml culture, withdraw 26 ml of Medium A and 3 ml of Medium B (10% of the final culture) and transfer into the 125 ml Erlenmeyer culture flask and gently mix by shaking (hereafter termed as fresh culture medium). 4. Transfer one vial of cells containing HEK293F cells, frozen at -80 °C, onto ice and move to the culture room. Note: HEK293F cells are supplied at a density of 1 x 10 7 cells/ml.
5. Warm the vial gently in water-bath at 37 °C to partially thaw the cells (it takes approximately one min and cells should not be completely thawed). Sterilize the outside of the vial with the 70% ethanol in water solution and move it into the biosafety cabinet. 6. Using 1 ml pipette, withdraw the cell suspension (approximately 0.7 ml) and transfer into the 125 ml Erlenmeyer flask containing 29 ml of fresh culture medium. Close the cover of the culture flask and move it into the incubated shaker. the aliquot of cells (4 ml, this volume was determined according to step 1.2.6) from the culture and transfer it to the flask containing fresh culture medium. 10. Transfer both the cultures from the biosafety cabinet to the incubator shaker set according to 1.1.1. Grow cells to an approximate density of 2-3 x 10 6 live cells/ml.
Note: The approximate doubling time of cells is 32 hr. It will take 3-4 days to reach this density. Incubate the cells for 3-4 passages to have stable growth pattern of cells prior to the first transfection. 42 . A brief procedure for DNA preparation is explained here:
Prepare Materials for Transfection
1. Grow a culture of chemically-competent Escherichia coli cells transformed with the pGEn2 vector in 1 L of LB medium (Tryptone-10 g/L, yeast extract-5 g/L and sodium chloride-10 g/L) supplemented with 100 μg/ml ampicillin. E. coli is grown at 37 °C in a non-humidified, shaking incubator. 2. Purify the pGEn2 vector encoding target plasmid DNA according to the manufacturer's DNA purification protocol. 3. To ensure complete sterility of the plasmid DNA, perform the final isopropanol precipitation and resuspension steps of the DNA extraction procedures inside the biosafety cabinet. 4. Add the volume of isopropanol (specified in the plasmid preparation kit) to the eluted DNA and centrifuge at 10,000 x g for 10 min. Sterilize the outside of the DNA container with 70 % ethanol in water solution and transfer it inside the biosafety cabinet. Discard the isopropanol supernatant using a pipette and air-dry the DNA pellet. Once dry, resuspend the pellet in sterile 10 mM Tris buffer, pH 8.0.
2. Centrifuge the collected supernatant with expressed protein at high speed (14,000 g for 10 min) to remove any remaining cell debris. Collect by decanting into a fresh tube. Discard the pellet as a biohazard. 3. Collect a 10 μl aliquot of the supernatant and additionally collect a small sample at each protein purification step to analyze the sample by SDS-PAGE (described in Section 5). Load the clarified supernatant and collect the flow through. 4. Wash the column with 3-column volumes of buffer A and elute the protein with 5-column volumes of 100 mM glycine, pH 3.0. Collect the eluate in tubes containing one-half volume of 1 M TRIS buffer, pH of 8.0 to rapidly neutralize the pH. 5. Wash the column with 10 column volumes of buffer A and store for future use. 6. Buffer exchange the eluted protein with at least a 10-fold excess of buffer A using 10 kDa molecular weight cut-off centrifugal filters. Note:
Do not concentrate the eluted sample to a very low volume (<2 ml) in the eluted buffer. Use the centrifugal filters to exchange the buffer with buffer A. 7. Store purified protein at 4 °C until next use.
Note: Protein expressed in the supernatant can be purified by affinity columns selected on the basis of protein's properties or the use of affinity tags. For a typical purification procedure, Protein A column can be used for IgG or Fc fragments or nickel column can be used for proteins expressed with a poly-histidine tag. Here, is a description of the purification steps for IgG1-Fc using a Protein A column.
Analysis of Protein by SDS-PAGE
1. Dilute the aliquots (7.5 μl) of each sample with an equal volume of 2x loading buffer (0.125 M Tris, pH 8.0, 4% SDS, 10% β-mercaptoethanol, 20% glycerol, and 0.01% bromophenol blue). 2. Boil the mixture at 90 °C for 5 min using a heat block or water bath. Centrifuge the samples at 10,000 g for 1 min. Load the prepared gel with 5 μl of marker protein and 14 μl of samples for analyses using a 20 μl pipette with a disposable tip. 3. Run one gel at 25 milliamps for 60 min. Once the electrophoresis step is complete, transfer the gel to a container with 1 L of water and microwave for 5 min. 4. Stain the gel with staining solution (40% ethanol, 10% acetic acid and 0.1% coomassie brilliant blue) for 2 hr and destain in water.
Glycans Analysis by Mass Spectrometry
1. Analyze glycans as described previously 44 . Briefly, 75 μg of IgG1-Fc was trypsinized, then treated by PNGaseF for the release of glycans 45 . Released glycans were permethylated and analyzed by using matrix-assisted laser-desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS). Materials section for an example with appropriate volumes. 3. For transfection, follow steps of "3. Establishing a transient transfection" using fresh culture medium substituted with labeled amino acid residues as prepared above. 4. After 24 hr of transfection, on the day of culture dilution, withdraw 5.0 ml of prewarmed Medium B, 40 ml of prewarmed Medium A and a freshly autoclaved 4 ml aliquot of the amino acid mixture (prepared as in step 7.1.1. above) and add 1 ml prewarmed stock solution of VPA solution to prepare 50 ml of fresh dilution culture medium with a final concentration of 4.4 mM of VPA. Add this medium to the transfection culture using a sterile serological pipette. 5. Transfer the transfected culture into the biosafety cabinet after sterilizing the exterior of the flask with a 70% ethanol in water solution, add the prepared dilution medium and transfer the flask back to the incubated shaker. Note: Medium A is a chemically defined, serum-free medium. Thus, it is possible to prepare a different formulation. Contact the supplier to obtain a custom Medium A preparation that lacks certain amino acids. It is possible to have all amino acids left out, however, we prefer to use medium that lacks only few select residues because a complete dropout medium would require adjustment of osmolarity after supplementation. We chose a Lys-Tyr-Phe dropout medium that can be supplemented and does not require osmolarity adjustment. Furthermore, the Medium A supplier does not freely share the concentrations of medium components; we used 100 mg/L each for Lys, Tyr and Phe with success. Volumes of the transfection and expression medium must be adjusted to account for the added amino acids. Here are the adjustments to the protocol above for isotope labeling 2. Supplement the Transfection with a Small Molecule 1. Prepare 100 mM stock solution of 2-deoxy-2-fluoro-l-fucose using autoclaved water and sterilize this solution using a 0.22 μM filter. 2. For a 50 ml culture, add 125 μl (at 250 μM) of the fucose analog solution to the transfection and dilution media. Note: We neglected to perform any further volume adjustment because adding the substituent at this concentration accounts for only 0.25% of the total culture volume .It is possible to modify the expression using small molecule inhibitors of glycan processing. Here we describe the conditions for including 2-deoxy-2-fluoro-l-fucose, an inhibitor of glycan fucosylation. We found >90% reduction in fucosylation by adding the fucose analog at a concentration of 250 μM in the transfection and dilution media.
Protocol Adjustments for Special Scenarios
Representative Results
High-level protein expression and purity
This optimized expression system generated a high yield of glycosylated proteins. A typical pattern is shown in the expression of IgG1-Fc (Figure 1) . In this case, Day 0 is the transfection day followed by Day 1 (dilution) and subsequent culture days up to Day 5. Protein expression is analyzed using the soluble expression fraction in the crude medium. A very small amount of protein expression was observed in Day 1 as the culture aliquot was withdrawn 3 hr after culture dilution. This is easier to visualize with GFP-tagged proteins that display a distinct green color in the culture medium. Such an increase was observed for in the expression of the GFP-FcγRIIIa and GFP-ST6GalI from Day 2 to Day 5. No significant increase in the expression was observed between Day 4 and Day 5. At Day 5, the cells were <50% viable and hence culture was harvested to limit proteolysis. Affinity purification using a Protein A column for IgG1 Fc or nickel column for GFP-FcγRIIIa resulted in proteins with high purity (>99%; Figure 2 ), yield ( Table 1 ) and complete glycosylation (data not shown).
15
N or 13 
C Isotope labeling of proteins and glycans
This system efficiently expressed isotopically-enriched IgG1 Fc according the described protocol. Although a small reduction in protein yield was observed (25-50%), well-dispersed signals were seen in a 2d NMR spectrum that correlates the resonance frequency of 1 H atoms and the directly bonded amide 15 N atoms (Figure 3) . This level of expression permits efficient protein production on the scale required for structurebased studies (typically 2-20 mg of protein) and illustrates the successful incorporation of the labeled isotopes into the protein. The high degree of similarity between this spectrum and published spectra indicate a high degree of protein labeling occurred with minimal scrambling of the 15 N labels 43 .
Producing proteins with different N-glycans
Different glycoforms were produced with the HEK293F and HEK293S cells. Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) analyses of the enzymatically-released N-glycans showed the expected glycoforms (Figure 4) . Proteins expressed from HEK293S cells harbored N-glycans that were of the Man 5 GlcNAc 2 form and contained no fucose (Figure 4) . Glycans from HEK293F-expressed material were complex-type, biantennary forms with core fucose and mostly having terminal N-acetylglucosamine (GlcNAc) or small proportion of monoor di-galactosylated (Gal) forms. Though it is not know what the native N-glycans of ST6GalI and FcγRIIIa are, the glycan profile for IgG1 Fc is highly similar to IgG1 Fc purified from human serum 46 . The major differences include the degree of modification; IgG1 Fc from human serum shows a higher degree of galactosylation than observed for the HEK293F expression. Addition of 2-deoxy-2-fluoro-l-fucose, an inhibitor of glycan fucosylation, to an expression conducted using the HEK293F cell line showed a dramatic >90% reduction in fucose incorporation (Figure 4 ). 
Discussion
This protocol illustrates protein expression via the transient transfection of HEK293F or S cells. The optimal transfection conditions established in the Barb and Moremen labs employ a critical combination of cell density and reagent concentrations to achieve high efficiency transfection. Critical considerations when implementing this protocol include: maintaining a stable culture prior to transfection (with consistent culture doubling times); transfection of actively growing cells (achieved by diluting cells to 1 × 10 6 cells/ml 24 hr prior to transfection) with cell viability greater than 95%; cell density at transfection should be between 2.5-3.0 x 10 6 live cells/ml with a viability >95% (transfection density) in a culture containing 90% Medium A and 10% Medium B; and, adding DNA prior to PEI addition at 3 μg/ml and 9 μg/ml, respectively 31 ; at 24 hr post-transfection the culture is diluted 1:1 in medium containing 4.4 mM valproic acid to result in a concentration of 2.2 mM valprioc acid in the diluted culture; the production phase growth then continues in a humidified shake flask at 37 °C and 8% CO 2 for an additional 4-5 days. The vector described here is optimized and an important feature of the soluble protein expression system 32, 42 .
If a target protein fails to express, in addition to the factors listed above, multiple other variables may contribute to low yields. Ensure the protein coding DNA sequence contains codons optimized for human cells. This can be assessed with multiple online resources. Sterility throughout the procedure is paramount. An actively growing and pure culture of HEK293F cells should appear slightly grainy to the naked eye, and the medium should be mostly clear (particularly at cell densities <1.0 ×10 6 cells/ml).
Cultures contaminated with bacteria or fungus should be immediately removed to prevent spread. Is it important to maintain a healthy stock culture. This is achieved by inoculating these cultures at a cells density of 0.3 × 10 6 cells/ml. Lower inoculation densities can slow the growth rate by limiting the supply of various growth factors required for cell growth and division 48 . As cultures have been passaged for more than 25 or 30 times, a decrease in expression was observed. For this reason, cultures passaged more than 30 times are discarded.
. The transient transfection of HEK293 cells has shown great utility for producing soluble proteins and protein domains that are naturally targeted to the secretory pathway. It is likely that production of cytoplasmic or integral membrane proteins will require further optimization. A primary advantage of this system is the native substrates and machinery for protein production are present and available in the HEK293 cells 49 . This largely accounts to its advantages over other recombinant protein production methods such as bacteria with no or limited post-translational modifications, or yeast and baculovirus systems with correctly folded but different N-glycoforms incorporated 1, 50, 51 . Furthermore, the protocol described here shows the added capability to include low molecular weight compounds such as labeled amino acids, labeled glucose or small molecules designed to modify the N-glycan composition. The HEK293 cells also prove adept at expression of nonmammalian proteins, including plant enzymes, and supports co-expression of multiple polypeptides for the recovery of protein complexes (data not shown).
The structural and functional characterization of glycoproteins is often hampered by sample production challenges. The protein expression system described here surmounts this drawback by accomplishing post-translational modifications using the natural complement of sophisticated intracellular glycan processing enzymes 6 . This robust and simple protocol is proven for the transient transfection of suspension human HEK293 cells. This method demonstrated significant glycoprotein yield (>95 mg/L) with three N-glycosylated proteins and can accommodate supplements such as labeled amino acid residues or the small molecule chemical inhibitor 2-deoxy-2-fluoro-l-fucose. The expressed glycoproteins can be further remodeled post-purification to prepare a wide range of defined glycoforms 52 .
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